The Recall Desk
SevereFDA (Drugs)·D-0180-2025·Announced 2025-01-15

Clonazepam Tablets Recalled Due to Incorrect Carton Labeling

Endo USA recalls clonazepam tablets because some cartons are labeled with incorrect declared strength. The medication inside the blister strips contains the correct strength.

What this means for you

Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.

Our severity reasoning: FDA Class I designation establishes a minimum severity score of 4 per the classification rules. Although no illnesses or injuries have been reported, the labeling discrepancy on a controlled benzodiazepine carton justifies this severity level.

Plain-English summary

Endo USA, Inc. is recalling Clonazepam Orally Disintegrating Tablets USP 0.25 mg because some product cartons are labeled with incorrect declared strength. However, the blister strips inside the product carton reflect the correct strength.

The recall affects 72,973 cartons distributed nationwide. The affected cartons are from lots 550142801, 550142901, 550143001, 550143101, 550143201, 550143301, 550143401, 550147201, and 550147401, with an expiration date of August 31, 2026. The product is distributed by PAR Pharmaceutical, Chestnut Ridge, New York.

The recalled product

Product
CLONAZEPAM (CLONAZEPAM)
Brand
CLONAZEPAM
Manufacturer
Endo USA, Inc.
Hazard
  • mis-labeling

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (10)

  • Lot #s: 550142801
  • 550142901
  • 550143001
  • 550143101
  • 550143201
  • 550143301
  • 550143401
  • 550147201
  • 550147401
  • Exp. 08/31/2026.

Distribution

Distributed nationwide across the United States.